 | • レポートコード：MRC2-11QY12199 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はヒストプラズマ症治療のグローバル市場について調査・分析したレポートです。種類別（アムホテリシンB、イトラコナゾール、ケトコナゾール、その他）市場規模、用途別（病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別ヒストプラズマ症治療の競争状況、市場シェア ・世界のヒストプラズマ症治療市場：種類別市場規模 2015年-2020年（アムホテリシンB、イトラコナゾール、ケトコナゾール、その他） ・世界のヒストプラズマ症治療市場：種類別市場規模予測 2021年-2026年（アムホテリシンB、イトラコナゾール、ケトコナゾール、その他） ・世界のヒストプラズマ症治療市場：用途別市場規模 2015年-2020年（病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース） ・世界のヒストプラズマ症治療市場：用途別市場規模予測 2021年-2026年（病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース） ・北米のヒストプラズマ症治療市場分析：米国、カナダ ・ヨーロッパのヒストプラズマ症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのヒストプラズマ症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のヒストプラズマ症治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのヒストプラズマ症治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol Myers Squibb、Sigma tau pharmaceuticals Inc.、Three rivers pharmaceuticals、Astellas pharma US Inc.、Abbott laboratories、Abraxis pharmaceutical products、Teva parenteral medicines Inc.、X gen pharmaceuticals Inc. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Histoplasmosis is an infection that occurs from breathing spores of a fungus called Histoplasma capsulatum. Histoplasmosis is a fungal infection that occurs throughout the world. Histoplasma fungus grows as a mold in the soil. The soil that contains the droppings of bat or birds usually contains large amount of this fungus. The people with weakened immune system are usually more prone and increases the risk of being affected or reactivated with histoplasmosis. Usually people very young, old people and people affected with cancer, AIDS or organ transplant have severe symptoms. The people with chronic lung disease such as bronchiectasis or emphysema have high risk of severe pain. The common symptoms of histoplasmosis is fever, chills, cough, chest pain, red skin bumps, mouth sores etc. In some patients suffering from histoplasmosis may spread throughout the body and cause irritation and swelling in response to infection.
Certain symptoms also includes chest pain from swelling in lining of heart, neck stiffness etc. The disease is usually diagnosed with biopsy of lungs, skin, liver or bone marrow. Certain blood and urine test also help in detection histoplasmosis proteins or antibodies of the fungus in body. In some cases doctors also perform Chest CT scan, Chest X-ray, Bronchoscopy etc.
Market Analysis and Insights: Global Histoplasmosis Treatment Market
The global Histoplasmosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Histoplasmosis Treatment Scope and Market Size
Histoplasmosis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Histoplasmosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bristol Myers Squibb
Sigma tau pharmaceuticals Inc.
Three rivers pharmaceuticals
Astellas pharma US Inc.
Abbott laboratories
Abraxis pharmaceutical products
Teva parenteral medicines Inc.
X gen pharmaceuticals Inc.
Market segment by Type, the product can be split into
Amphotericin B
Itraconazole
Ketoconazole
Other
Market segment by Application, split into
Hospitals Pharmacies
Private clinics
Drug stores and retail pharmacy
E-commerce
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Histoplasmosis Treatment Revenue
1.4 Market by Type
1.4.1 Global Histoplasmosis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Amphotericin B
1.4.3 Itraconazole
1.4.4 Ketoconazole
1.4.5 Other
1.5 Market by Application
1.5.1 Global Histoplasmosis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals Pharmacies
1.5.3 Private clinics
1.5.4 Drug stores and retail pharmacy
1.5.5 E-commerce
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Histoplasmosis Treatment Market Perspective (2015-2026)
2.2 Global Histoplasmosis Treatment Growth Trends by Regions
2.2.1 Histoplasmosis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Histoplasmosis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Histoplasmosis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Histoplasmosis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Histoplasmosis Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Histoplasmosis Treatment Players by Market Size
3.1.1 Global Top Histoplasmosis Treatment Players by Revenue (2015-2020)
3.1.2 Global Histoplasmosis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Histoplasmosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Histoplasmosis Treatment Market Concentration Ratio
3.2.1 Global Histoplasmosis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Histoplasmosis Treatment Revenue in 2019
3.3 Histoplasmosis Treatment Key Players Head office and Area Served
3.4 Key Players Histoplasmosis Treatment Product Solution and Service
3.5 Date of Enter into Histoplasmosis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Histoplasmosis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Histoplasmosis Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Histoplasmosis Treatment Market Size by Application (2015-2020)
5.2 Global Histoplasmosis Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Histoplasmosis Treatment Market Size (2015-2020)
6.2 Histoplasmosis Treatment Key Players in North America (2019-2020)
6.3 North America Histoplasmosis Treatment Market Size by Type (2015-2020)
6.4 North America Histoplasmosis Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Histoplasmosis Treatment Market Size (2015-2020)
7.2 Histoplasmosis Treatment Key Players in Europe (2019-2020)
7.3 Europe Histoplasmosis Treatment Market Size by Type (2015-2020)
7.4 Europe Histoplasmosis Treatment Market Size by Application (2015-2020)
8 China
8.1 China Histoplasmosis Treatment Market Size (2015-2020)
8.2 Histoplasmosis Treatment Key Players in China (2019-2020)
8.3 China Histoplasmosis Treatment Market Size by Type (2015-2020)
8.4 China Histoplasmosis Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Histoplasmosis Treatment Market Size (2015-2020)
9.2 Histoplasmosis Treatment Key Players in Japan (2019-2020)
9.3 Japan Histoplasmosis Treatment Market Size by Type (2015-2020)
9.4 Japan Histoplasmosis Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Histoplasmosis Treatment Market Size (2015-2020)
10.2 Histoplasmosis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Histoplasmosis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Histoplasmosis Treatment Market Size by Application (2015-2020)
11 India
11.1 India Histoplasmosis Treatment Market Size (2015-2020)
11.2 Histoplasmosis Treatment Key Players in India (2019-2020)
11.3 India Histoplasmosis Treatment Market Size by Type (2015-2020)
11.4 India Histoplasmosis Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Histoplasmosis Treatment Market Size (2015-2020)
12.2 Histoplasmosis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Histoplasmosis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Histoplasmosis Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Details
13.1.2 Bristol Myers Squibb Business Overview
13.1.3 Bristol Myers Squibb Histoplasmosis Treatment Introduction
13.1.4 Bristol Myers Squibb Revenue in Histoplasmosis Treatment Business (2015-2020))
13.1.5 Bristol Myers Squibb Recent Development
13.2 Sigma tau pharmaceuticals Inc.
13.2.1 Sigma tau pharmaceuticals Inc. Company Details
13.2.2 Sigma tau pharmaceuticals Inc. Business Overview
13.2.3 Sigma tau pharmaceuticals Inc. Histoplasmosis Treatment Introduction
13.2.4 Sigma tau pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.2.5 Sigma tau pharmaceuticals Inc. Recent Development
13.3 Three rivers pharmaceuticals
13.3.1 Three rivers pharmaceuticals Company Details
13.3.2 Three rivers pharmaceuticals Business Overview
13.3.3 Three rivers pharmaceuticals Histoplasmosis Treatment Introduction
13.3.4 Three rivers pharmaceuticals Revenue in Histoplasmosis Treatment Business (2015-2020)
13.3.5 Three rivers pharmaceuticals Recent Development
13.4 Astellas pharma US Inc.
13.4.1 Astellas pharma US Inc. Company Details
13.4.2 Astellas pharma US Inc. Business Overview
13.4.3 Astellas pharma US Inc. Histoplasmosis Treatment Introduction
13.4.4 Astellas pharma US Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.4.5 Astellas pharma US Inc. Recent Development
13.5 Abbott laboratories
13.5.1 Abbott laboratories Company Details
13.5.2 Abbott laboratories Business Overview
13.5.3 Abbott laboratories Histoplasmosis Treatment Introduction
13.5.4 Abbott laboratories Revenue in Histoplasmosis Treatment Business (2015-2020)
13.5.5 Abbott laboratories Recent Development
13.6 Abraxis pharmaceutical products
13.6.1 Abraxis pharmaceutical products Company Details
13.6.2 Abraxis pharmaceutical products Business Overview
13.6.3 Abraxis pharmaceutical products Histoplasmosis Treatment Introduction
13.6.4 Abraxis pharmaceutical products Revenue in Histoplasmosis Treatment Business (2015-2020)
13.6.5 Abraxis pharmaceutical products Recent Development
13.7 Teva parenteral medicines Inc.
13.7.1 Teva parenteral medicines Inc. Company Details
13.7.2 Teva parenteral medicines Inc. Business Overview
13.7.3 Teva parenteral medicines Inc. Histoplasmosis Treatment Introduction
13.7.4 Teva parenteral medicines Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.7.5 Teva parenteral medicines Inc. Recent Development
13.8 X gen pharmaceuticals Inc.
13.8.1 X gen pharmaceuticals Inc. Company Details
13.8.2 X gen pharmaceuticals Inc. Business Overview
13.8.3 X gen pharmaceuticals Inc. Histoplasmosis Treatment Introduction
13.8.4 X gen pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.8.5 X gen pharmaceuticals Inc. Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Histoplasmosis Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Histoplasmosis Treatment Revenue
Table 3. Ranking of Global Top Histoplasmosis Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Histoplasmosis Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Amphotericin B
Table 6. Key Players of Itraconazole
Table 7. Key Players of Ketoconazole
Table 8. Key Players of Other
Table 9. Global Histoplasmosis Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Histoplasmosis Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Histoplasmosis Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Histoplasmosis Treatment Market Share by Regions (2015-2020)
Table 13. Global Histoplasmosis Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Histoplasmosis Treatment Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Histoplasmosis Treatment Market Growth Strategy
Table 19. Main Points Interviewed from Key Histoplasmosis Treatment Players
Table 20. Global Histoplasmosis Treatment Revenue by Players (2015-2020) (Million US$)
Table 21. Global Histoplasmosis Treatment Market Share by Players (2015-2020)
Table 22. Global Top Histoplasmosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Histoplasmosis Treatment as of 2019)
Table 23. Global Histoplasmosis Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Histoplasmosis Treatment Product Solution and Service
Table 26. Date of Enter into Histoplasmosis Treatment Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 29. Global Histoplasmosis Treatment Market Size Share by Type (2015-2020)
Table 30. Global Histoplasmosis Treatment Revenue Market Share by Type (2021-2026)
Table 31. Global Histoplasmosis Treatment Market Size Share by Application (2015-2020)
Table 32. Global Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 33. Global Histoplasmosis Treatment Market Size Share by Application (2021-2026)
Table 34. North America Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 36. North America Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 37. North America Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 38. North America Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 39. North America Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 40. Europe Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 42. Europe Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 44. Europe Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 46. China Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 47. China Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 48. China Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 49. China Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 50. China Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 51. China Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 52. Japan Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 54. Japan Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 56. Japan Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 60. Southeast Asia Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 62. Southeast Asia Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 64. India Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 65. India Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 66. India Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 67. India Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 68. India Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 69. India Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Histoplasmosis Treatment Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Histoplasmosis Treatment Market Share (2019-2020)
Table 72. Central & South America Histoplasmosis Treatment Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Histoplasmosis Treatment Market Share by Type (2015-2020)
Table 74. Central & South America Histoplasmosis Treatment Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Histoplasmosis Treatment Market Share by Application (2015-2020)
Table 76. Bristol Myers Squibb Company Details
Table 77. Bristol Myers Squibb Business Overview
Table 78. Bristol Myers Squibb Product
Table 79. Bristol Myers Squibb Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 80. Bristol Myers Squibb Recent Development
Table 81. Sigma tau pharmaceuticals Inc. Company Details
Table 82. Sigma tau pharmaceuticals Inc. Business Overview
Table 83. Sigma tau pharmaceuticals Inc. Product
Table 84. Sigma tau pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 85. Sigma tau pharmaceuticals Inc. Recent Development
Table 86. Three rivers pharmaceuticals Company Details
Table 87. Three rivers pharmaceuticals Business Overview
Table 88. Three rivers pharmaceuticals Product
Table 89. Three rivers pharmaceuticals Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 90. Three rivers pharmaceuticals Recent Development
Table 91. Astellas pharma US Inc. Company Details
Table 92. Astellas pharma US Inc. Business Overview
Table 93. Astellas pharma US Inc. Product
Table 94. Astellas pharma US Inc. Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 95. Astellas pharma US Inc. Recent Development
Table 96. Abbott laboratories Company Details
Table 97. Abbott laboratories Business Overview
Table 98. Abbott laboratories Product
Table 99. Abbott laboratories Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 100. Abbott laboratories Recent Development
Table 101. Abraxis pharmaceutical products Company Details
Table 102. Abraxis pharmaceutical products Business Overview
Table 103. Abraxis pharmaceutical products Product
Table 104. Abraxis pharmaceutical products Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 105. Abraxis pharmaceutical products Recent Development
Table 106. Teva parenteral medicines Inc. Company Details
Table 107. Teva parenteral medicines Inc. Business Overview
Table 108. Teva parenteral medicines Inc. Product
Table 109. Teva parenteral medicines Inc. Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 110. Teva parenteral medicines Inc. Recent Development
Table 111. X gen pharmaceuticals Inc. Business Overview
Table 112. X gen pharmaceuticals Inc. Product
Table 113. X gen pharmaceuticals Inc. Company Details
Table 114. X gen pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020) (Million US$)
Table 115. X gen pharmaceuticals Inc. Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Histoplasmosis Treatment Market Share by Type: 2020 VS 2026
Figure 2. Amphotericin B Features
Figure 3. Itraconazole Features
Figure 4. Ketoconazole Features
Figure 5. Other Features
Figure 6. Global Histoplasmosis Treatment Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Pharmacies Case Studies
Figure 8. Private clinics Case Studies
Figure 9. Drug stores and retail pharmacy Case Studies
Figure 10. E-commerce Case Studies
Figure 11. Histoplasmosis Treatment Report Years Considered
Figure 12. Global Histoplasmosis Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Histoplasmosis Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Histoplasmosis Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Histoplasmosis Treatment Market Share by Players in 2019
Figure 17. Global Top Histoplasmosis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Histoplasmosis Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Histoplasmosis Treatment Revenue in 2019
Figure 19. North America Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Histoplasmosis Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
クッシング病治療の世界市場（～2026年） Cushing disease is caused by tumour in the pituitary gland which leads to excessive secretion of a hormone called adrenocorticotrophic (ACTH), which in turn leads to increasing levels of cortisol in the body. Cortisol is a steroid hormone released by the adrenal glands and helps the body to deal wit…- 尿路感染症治療の世界市場（～2026年） Urinary tract infection (UTI) is a common infections of the urinary tract, which consists of the kidneys, ureters, bladder, urethra or prostate gland. This trend of increment in the prevalence rate of diabetes among adults is expected to continue during the forecast period. Therefore, with increasin…
- 萎縮性胃炎治療の世界市場（～2026年） Atopic gastritis is chronic inflammation of gastric mucosa, and it is a histopathological condition associated with gastric glandular cell and replacement by fibrous tissue, intestinal type epithelium, and pyloric type glands. It mainly associated H. Pylori bacterial infection, and autoimmunity dire…
- ドラベ症候群治療の世界市場（～2026年） Dravet syndrome is a rare, severe form of intractable epilepsy. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells. Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include …
- クッシング症候群治療の世界市場（～2026年） Cushing's syndrome involves symptoms such as high blood pressure, abdominal obesity, round red face, a fatty lump between the shoulders, weak muscles and bones, acne, fragile skin and others. Most Cushing's syndrome cases are caused by pituitary adenoma, and multiple endocrine neoplasia. In terms of…